This content is only available within our institutional offering.
11 Jan 2024
The Hardman & Co Monthly: January 2024
Volta Finance Limited (VTA:LON), 504 | Shield Therapeutics Plc (STX:LON), 1.4 | ICG Enterprise Trust PLC GBP (ICGT:LON), 1,204 | NB Private Equity Partners Limited Class A (NBPE:LON), 1,636 | Real Estate Credit Investments Limited (RECI:LON), 117 | Apax Global Alpha Ltd. (APAX:LON), 142 | Arbuthnot Banking Group PLC (ARBB:LON), 1,065 | Advanced Oncotherapy Plc (AVO:LON), 1.9 | H&T Group plc (HAT:LON), 430
Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
The Hardman & Co Monthly: January 2024
Volta Finance Limited (VTA:LON), 504 | Shield Therapeutics Plc (STX:LON), 1.4 | ICG Enterprise Trust PLC GBP (ICGT:LON), 1,204 | NB Private Equity Partners Limited Class A (NBPE:LON), 1,636 | Real Estate Credit Investments Limited (RECI:LON), 117 | Apax Global Alpha Ltd. (APAX:LON), 142 | Arbuthnot Banking Group PLC (ARBB:LON), 1,065 | Advanced Oncotherapy Plc (AVO:LON), 1.9 | H&T Group plc (HAT:LON), 430
- Published:
11 Jan 2024 -
Author:
Martin Hall | Mark Thomas -
Pages:
28
The main function of the HHI is to monitor the performance, and to highlight the attractiveness, of life sciences investments over the long term, and to try to identify those stocks that have disruptive technologies that consistently allow them to outperform both the index and the markets. Many of the 52 constituents of the index are high-risk, still being in the development stage, with micro-capitalisations and a long way from profitability. Despite this, some companies can still make extremely attractive returns for investors. However, although pharmaceutical, biotech and healthcare industries have defensive qualities, they are not immune from global economics.
Furthermore, the development and commercialisation of new drugs and medical technologies is capital-intensive. Given the interlink between inflation and interest rates, coupled with the increased risk-aversion of investors since the middle of 2022, there has been a financing crunch, which particularly affects smaller companies at the earlier stages of drug discovery and development with less robust financial profiles.
Download the file to read the article and January 2024 monthly.